Targets › ARSA
1 program from 1 company in 1 trial: 1 Phase 3; Metabolic and endocrine; next expected readout Mar 2031.
Lysosomal enzyme that catalyzes the hydrolysis of cerebroside-3-sulfate (N-acyl-1-beta-D-(3-O-sulfo)-galactosyl-sphing-4-enine) into cerebroside and sulfate, a reaction that requires the activator protein saposin B. Also involved in the catabolism of other sulfoglycosphingolipids such as SB1a and SM3 (beta-D-3-sulfogalactosyl-(1->4)-beta-D-glucosyl-(1<->1')-N-acylsphing-4-enine) (By similarity). (UniProt, P15289)
Open in Phaseline: the race on ARSA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Orchard Therapeutics | Atidarsagene Autotemcel (OTL-200) ARSA exogenous gene | ARSA | Phase 3 | Lysosomal Storage Diseases | Mar 2031 |
Lysosomal Storage Diseases (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.